

Bone Marrow and Stem Cell Transplantation Committee

**Friday, October 21, 2022
10:30 AM - 12:00 PM CT**

1. Active Protocol Updates

- a. SWOG1803 (Krishnan PI): Phase III Intergroup. Phase III Study of Daratumumab (NSC-791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy: Amrita Krishnan
- b. Alliance 051301: Randomized double blind phase III study of Ibrutinib during and following ASCT vs placebo in patients with R/R DLBCL of the ABC subtype: Patrick Stiff
- c. ECOG A4151: Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission: Brian Till

2. Pending Trials

- a. Randomized Phase II Trial of consolidation therapy after an incomplete remission following commercial CAR-T cell infusion for relapsed/refractory DLBCL: Nasheed Hossain/Brian Hess.
- b. ECOG-led chemotherapy vs immunotherapy salvage therapy prior to autologous stem cell transplantation for relapsed/refractory Hodgkin's Lymphoma: Dr. Vaishalee Kenkre
- c. Randomized trial of autologous stem cell transplantation for patients responding to induction therapy of Daratumumab-CyBorD for light chain amyloidosis: Patrick Hagen
- d. MyeloMATCH AML Tier 3 BMT consolidation/maintenance trial: Patrick Stiff; with discussion of RIC with venetoclax as part of transplant regimen and for first 100 days post-transplant: Dr Matthew Wieduwilt
- e. Randomized trial of autotransplant in CR1 for PTCL: Dr Marc Hoffman